Drug
Axelopran clinical trials
Also written TD-1211.
- studies test it
- 10
- open now
- 3
- in phase 3
- 0
- first study started
- 2010
Keep track of what changes. Save the axelopran studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 2
Glycyx Therapeutics (8) · John Kirkwood (1) · HealthPartners Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses axelopran is read from its arms, and is right about nine times in ten.
Testing it · 10
- Axelopran and Nivolumab in PD-1-Refractory Metastatic MelanomaRecruitingPhase 1/2John KirkwoodNCT07631325Written as Axelopran
- A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck CancerNot yet recruitingPhase 1/2Glycyx TherapeuticsNCT07662720Written as axelopran
- Axelopran for Advanced Cancer in Patients Receiving OpioidsRecruitingPhase 2HealthPartners InstituteNCT07354919Written as axelopran
- TD-1211 IV/Oral Mass Balance StudyCompletedPhase 1Glycyx TherapeuticsNCT01702194Written as TD-1211 IV [C14]
- A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced ConstipationCompletedPhase 2Glycyx TherapeuticsNCT01459926Written as TD-1211
- A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced ConstipationCompletedPhase 2Glycyx TherapeuticsNCT01333540Written as TD-1211
- A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced ConstipationCompletedPhase 1/2Glycyx TherapeuticsNCT01040637Written as TD-1211
- A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)CompletedPhase 2Glycyx TherapeuticsNCT01401985Written as TD-1211
- A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211CompletedPhase 1Glycyx TherapeuticsNCT01568411Written as TD-1211
- TD-1211 Single-Dose Study in Elderly and Young Healthy SubjectsCompletedPhase 1Glycyx TherapeuticsNCT01655771Written as TD-1211 Dose 1
Codes
What other systems call axelopran · ClinicalTrials.gg INT006400
- UNII (FDA) 85U7ROB149AXELOPRANConfirmed FDA, Wikidata
- Wikidata Q20707800axelopranConfirmed FDA, Wikidata
- NCI Thesaurus C171856AxelopranOne source FDA
- DrugBank DB12013One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 85U7ROB149 | AXELOPRAN | Confirmed FDA, Wikidata |
| Wikidata | Q20707800 | axelopran | Confirmed FDA, Wikidata |
| NCI Thesaurus | C171856 | Axelopran | One source FDA |
| DrugBank | DB12013 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.